Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jul 12;3(7):596-601.
doi: 10.1021/ml300107e. Epub 2012 Jun 11.

Truncated Nucleosides as A(3) Adenosine Receptor Ligands: Combined 2-Arylethynyl and Bicyclohexane Substitutions

Affiliations

Truncated Nucleosides as A(3) Adenosine Receptor Ligands: Combined 2-Arylethynyl and Bicyclohexane Substitutions

Dilip K Tosh et al. ACS Med Chem Lett. .

Abstract

C2-Arylethynyladenosine-5'-N-methyluronamides containing a bicyclo[3.1.0]hexane ((N)-methanocarba) ring are selective A(3) adenosine receptor (AR) agonists. Similar 4'-truncated C2-arylethynyl-(N)-methanocarba nucleosides containing alkyl or alkylaryl groups at the N(6) position were low-efficacy agonists or antagonists of the human A(3)AR with high selectivity. Higher hA(3)AR affinity was associated with N(6)-methyl and ethyl (K(i) 3-6 nM), than with N(6)-arylalkyl groups. However, combined C2-phenylethynyl and N(6)-2-phenylethyl substitutions in selective antagonist 15 provided a K(i) of 20 nM. Differences between 4'-truncated and nontruncated analogues of extended C2-p-biphenylethynyl substitution suggested a ligand reorientation in AR binding, dominated by bulky N(6) groups in analogues lacking a stabilizing 5'-uronamide moiety. Thus, 4'-truncation of C2-arylethynyl-(N)-methanocarba adenosine derivatives is compatible with general preservation of A(3)AR selectivity, especially with small N(6) groups, but reduced efficacy in A(3)AR-induced inhibition of adenylate cyclase.

PubMed Disclaimer

Figures

Chart 1
Chart 1. (N)-Methanocarba-adenosine Derivatives as Selective A3AR Ligands (hAR Affinity in nM): Full Agonists in the 5′-N-Methyluronamide Series (1 and 3) and Truncated Nucleosides (2) That Act as A3AR Antagonists and Partial Agonists, Including the Present Target Structures (421)
Scheme 1
Scheme 1. Synthesis of Truncated (N)-Methanocarba-adenosine Analogues
Reagents: (i) 2-Iodo-6-chloropurine, Ph3P, DIAD, THF, rt. (ii) R1NH2, Et3N, MeOH, rt. (iii) Substituted HC≡C-Ph-R2, Pd(PPh3)2Cl2, CuI, Et3N, DMF, rt. (iv) 50% TFA (aq.), MeOH:CH2Cl2 (3:1), rt.

Similar articles

Cited by

References

    1. Fredholm B. B.; IJzerman A. P.; Jacobson K. A.; Linden J.; Müller C. Nomenclature and classification of adenosine receptors—An update. Pharmacol. Rev. 2011, 63, 1–34. - PMC - PubMed
    1. Fishman P.; Bar-Yehuda S.; Liang B. T.; Jacobson K. A. Pharmacological and therapeutic effects of A3 adenosine receptor (A3AR) agonists. Drug Discovery Today 2012, 17, 359–366. - PMC - PubMed
    1. Gessi S.; Merighi S.; Varani K.; Cattabriga E.; Benini A.; Mirandola P.; Leung E.; MacLennan S.; Feo C.; Baraldi S.; Borea P. A. Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: focus on the A3 adenosine subtype. J. Cell. Physiol. 2007, 211, 826–836. - PubMed
    1. Gessi S.; Merighi S.; Sacchetto V.; Simioni C.; Borea P. A. Adenosine receptors and cancer. Biochem. Biophys. Acta 2011, 1808, 1400–1412. - PubMed
    1. Cheong S. L.; Federico S.; Venkatesan G.; Mandel A. L.; Shao Y. M.; Moro S.; Spalluto G.; Pastorin G. The A3 adenosine receptor as multifaceted therapeutic target: pharmacology, medicinal chemistry, and in silico approaches. Med. Res. Rev. 2012, 10.1002/med.20254. - DOI - PubMed